Chinese fermentation producers with roots in pharmaceuticals, amino acids and vitamins are directing spare capacity toward mycoprotein, yeast-derived proteins and precision-fermented fats, according to vegconomist and Green Queen’s coverage of a Good Food Institute APAC report. Vegconomist identified Australian biotechnology and geopolitics researcher Dirk van der Kley as the report’s author.
The report’s central finding is that China’s established factories, specialist workforce, supply chains and operating costs could change the economics of alternative-protein manufacturing, according to both publications. Green Queen emphasizes links to food security and biotechnology policy, while vegconomist highlights declining returns and government-backed biomanufacturing. The accounts differ in emphasis rather than substance.
China represented about half of worldwide amino-acid exports and 38% of vitamin exports in 2024, vegconomist reported from the study. According to the publication, an August 2025 government list named 36 biomanufactured products for development, including three connected directly to alternative proteins. Vegconomist also reported that Fushine Biotech is enlarging a 1,200-tonne mycoprotein line, while More Meat is developing a 20,000-tonne plant through a joint venture.
The commercial trade-offs remain unsettled. Both outlets identify intellectual-property leakage, tariffs, political tension and dependence on overseas production partners as concerns for foreign companies. Green Queen also cited experts who compared a US facility costing $100 million with an equivalent Chinese project costing roughly ¥100 million, or $15 million. Green Queen reported that regulatory access for proteins made with genetically engineered microorganisms has improved, though uncertainty around trade and technology controls persists.
CONCLUSION For overseas businesses, GFI APAC says the practical significance is that working with China need not be an all-or-nothing choice. The report presents relationship-building, pilots, manufacturing partnerships and strategic investment as possible approaches, making the form of engagement the next issue to watch.